Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolbutamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | FBP1 | P09467 | 7/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolbutamide SCHEMBL1536920 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL28184306 | 0.98 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL11356450 | 0.98 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL668223 | 0.98 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL11357518 | 0.98 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL4367531 | 0.98 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL28046582 | 0.98 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL7551276 | 0.98 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL140363 | 0.98 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL8733982 | 0.97 | ALDH1A1 (0.94) | ALDH1A1LMNACYP2C9TSHRALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 45670 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124282-A1 | DECORIN FOR ITS USE IN THE TREATMENT OF DIABETES | CENTRE EUROPEEN D'ETUDE DU DIABETE (FR) | 2026-05-07 | — | — | US | claimed |
| US-12616685-B2 | Concomitant administration of glucocorticoid receptor modulator relacorilant and CYP2C9 substrates | CORCEPT THERAPEUTICS INCORPORATED (US) | 2026-05-05 | — | — | US | claimed |
| US-20260115210-A1 | METHOD FOR TREATING SUBJECTS SUFFERING FROM CENTRAL NERVOUS SYSTEM CONTUSIONS | REMEDY PHARMACEUTICALS, INC. (US) | 2026-04-30 | — | — | US | claimed |
| US-12611416-B2 | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema | REMEDY PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | claimed |
| EP-4717267-A1 | SYNERGISTIC COMBINATION FOR TREATING CANCER | FUNDACION UNIVERSITARIA SAN ANTONIO (UCAM) (ES) | 2026-04-01 | — | — | EP | claimed |
| EP-4714925-A1 | A REACTIVE RESIN COMPOSITION COMPRISING A PEROXIDE-FREE INITIATOR SYSTEM | Hilti Aktiengesellschaft (LI) | 2026-03-25 | — | — | EP | claimed |
| EP-4714927-A1 | A REACTIVE RESIN COMPOSITION COMPRISING A PEROXIDE-FREE INITIATOR SYSTEM WITH A SULFINATE AND A TERTIARY AMINE | Hilti Aktiengesellschaft (LI) | 2026-03-25 | — | — | EP | claimed |
| EP-4279532-B1 | CROSSLINKED POLYGLYCEROL PARTIAL ESTERS | EVONIK OPERATIONS GMBH (DE) | 2026-03-25 | — | — | EP | claimed |
| EP-4714926-A1 | A REACTIVE RESIN COMPOSITION COMPRISING A PEROXIDE-FREE INITIATOR SYSTEM WITH A TERTIARY AMINE | Hilti Aktiengesellschaft (LI) | 2026-03-25 | — | — | EP | claimed |
| EP-4714928-A1 | A REACTIVE RESIN COMPOSITION COMPRISING A PEROXIDE-FREE INITIATOR SYSTEM WITH A HETEROCYCLIC COMPOUND COMPRISING AT LEAST ONE N-N SINGLE BOND | Hilti Aktiengesellschaft (LI) | 2026-03-25 | — | — | EP | claimed |
| EP-0007911-A4 | ZINC AND/OR CERIUM CONTAINING SULFONYLUREA HYPOGLYCEMIC AGENTS, PREPARATION AND USE THEREOF. | RESEARCH CORP (US) | 1981-02-25 | — | — | EP | claimed |
| US-4195094-A | Zinc containing hypoglycemic agents | RESEARCH CORPORATION (US) | 1980-03-25 | — | — | US | claimed |
| EP-0007911-A1 | ZINC AND/OR CERIUM CONTAINING SULFONYLUREA HYPOGLYCEMIC AGENTS, PREPARATION AND USE THEREOF | Research Corporation (US) | 1980-02-06 | — | — | EP | claimed |
| WO-1979000435-A1 | ZINC AND/OR CERIUM CONTAINING SULFONYLUREA HYPOGLYCEMIC AGENTS,PREPARATION AND USE THEREOF | RESEARCH CORP (US) | 1979-07-12 | — | — | WO | claimed |
| US-4146613-A | ORAL ANTI-DIABETIC DRUG COMPOSITION | THERA GESELLSCHAFT FUR PATENTVERWERTUNG MBH (DE) | 1979-03-27 | — | — | US | claimed |
| EP-0001124-A1 | Drug mixtures for improving the utilisation of glucose in the cells and to reduce the bloodsugar level | THERA Gesellschaft für Patentverwertung mbH (DE) | 1979-03-21 | — | — | EP | claimed |
| US-4082842-A | SULFONYLUREA-TYPE HYPOGLYCEMIC, ASCORBIC ACID, SULFAMETHOXYPYRIDAZINE | NAHLE ARMANDO | 1978-04-04 | — | — | US | claimed |
| US-4036227-A | Osmotic releasing device having a plurality of release rate patterns | ALZA CORPORATION (US) | 1977-07-19 | — | — | US | claimed |
| US-4014334-A | Laminated osmotic system for dispensing beneficial agent | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
| US-3977404-A | OSMOTIC DEVICE HAVING MICROPOROUS RESERVOIR | ALZA CORPORATION (US) | 1976-08-31 | — | — | US | claimed |